...
机译:甲状腺素甲普(ABT-414)单药治疗EGFR-amplified,反复性胶质细胞瘤的疗效的疗效:多中心,国际研究的结果
Brain Tumor Center Erasmus MC Cancer Institute;
School of Cancer Medicine La Trobe University;
Department of Neurology and Herbert Irving Comprehensive Cancer Center Columbia University Medical;
Northwestern University;
NorthShore University Health System;
Department of Neurological Surgery University of California San Francisco;
Department of Medical Oncology School of Medicine University of Queensland Royal Brisbane and;
Henry Ford Health System;
University of Alabama at Birmingham;
South Texas Accelerated Research Therapeutics (START);
The University of Texas MD Anderson Cancer Center;
NHMRC Clinical Trials Centre University of Sydney;
Medical Oncology Royal North Shore Hospital;
Henry Ford Health System;
School of Cancer Medicine La Trobe University;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
AbbVie Inc.;
Dana-Farber Cancer Institute;
ABT-414; Depatuxizumab mafodotin; EGFR; Antibody–drug conjugate; Recurrent glioblastoma;
机译:甲状腺素甲普(ABT-414)单药治疗EGFR-amplified,反复性胶质细胞瘤的疗效的疗效:多中心,国际研究的结果
机译:新型抗体-药物缀合物(ADC),ABT-414作为单药在表皮生长因子受体(EGFR)增强(EGFRAMP),复发性胶质母细胞增生(RGBM)中的疗效
机译:新型抗体-药物缀合物(ADC)ABT-414作为单药在表皮生长因子受体(EGFR)增强的复发性胶质母细胞增生(GBM)中的疗效
机译:Cerna搜索方法鉴定了EGFR DNA扩增肺腺癌患者的核激活的亚组
机译:诊断为念珠菌血症的生存时间:流行病学生存方法在Mycoses Study Group多中心住院念珠菌血症患者观察研究中的应用。
机译:Depatuxizumab mafodotin(ABT-414)单一疗法在EGFR扩增的复发性胶质母细胞瘤患者中的疗效:一项来自多中心国际研究的结果
机译:路径29。与反复胶质母细胞瘤患者的响应和抗甲状腺蛋白酶(ABT-414)相关的分子决定簇